Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Terminated × Standard of Care × Clear all

Phase

Phase NA 10 Phase 3 10 Phase 2 8 Phase 1 4 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1

Status

Completed 6 Recruiting 3 Unknown 2 Withdrawn 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 1 Colorectal Neoplasms 1

Interventions

Sodium Chloride 4 Saline Solution 4 Pregabalin 4 Ketamine 4 Fentanyl 4 Bevacizumab 4 Tranexamic Acid 3 Photochemotherapy 3 Metformin 3 Letrozole 3 Docetaxel 3 Cyclophosphamide 3 ulipristal acetate 2 sodium glycididazole 2 nilotinib 2 liposomal doxorubicin 2 human papillomavirus vaccine, L1 type 16, 18 2 fludarabine 2 fluciclovine F-18 2 epoetin beta 2 aldesleukin 2 Trastuzumab 2 Surveys and Questionnaires 2 Sorafenib 2 Sofosbuvir 2 Rituximab 2 Ribavirin 2 Pemetrexed 2 Paclitaxel 2 Methotrexate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01468623 2023-07-19

PROFUSE

Myriad Genetic Laboratories, Inc.

Phase 4 Terminated

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡